Evidence map›Paper›PMID 33420646›Full record

ReviewCurrent atherosclerosis reports2021

Novel Functions of Endothelial Scavenger Receptor Class B Type I.

Liming Yu, Yao Dai, Chieko Mineo

Open access · greenAbstract readReview
In one paragraph

Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Different Pathways of Cellular Cholesterol Efflux.Cell biochemistry and biophysics · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Liming YuCenter for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Yao DaiCenter for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Chieko MineoCenter for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Chieko.Mineo@utsouthwestern.edu.ORCID 0000-0002-4978-6177
The University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

Endothelial Basis of Obesity-induced Insulin ResistanceR01DK110127 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MINEO, CHIEKO · 2016 to 2019
$1.8M
Dichotomous Role of Endothelial SR-BI in AtherosclerosisR01HL131597 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAUL, PHILIP W · 2017 to 2020
$1.6M
Endothelial SR-BI and Metabolic HealthR01HL126795 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI MINEO, CHIEKO · 2015 to 2018
$1.6M
NHLBI NIH HHS R01 HL126795NHLBI NIH HHS R01 HL131597NIDDK NIH HHS R01 DK110127
6 · The paper itself

Abstract

purpose of reviewScavenger receptor class B type I (SR-BI) serves a key role in the reverse cholesterol transport in the liver as the high-affinity receptor for HDL. SR-BI is abundantly expressed in endothelium, and earlier works indicate that the receptor mediates anti-atherogenic actions of HDL. However, more recent studies uncovered novel functions of endothelial SR-BI as a lipoprotein transporter, which regulates transcellular transport process of both LDL and HDL. This brief review focuses on the unique functions of endothelial SR-BI and how they influence atherogenesis. RECENT

findingsEarlier studies indicate that SR-BI facilitates anti-atherogenic actions of HDL through modulation of intracellular signaling to stimulate endothelial nitric oxide synthase. In vivo studies in global SR-BI knockout mice also showed a strong atheroprotective role of the receptor; however, a contribution of endothelial SR-BI to atherosclerosis process in vivo has not been fully appreciated. Recent studies using cultured endothelial cells and in mice with endothelial-specific deletion of the receptor revealed previously unappreciated pro-atherogenic actions of SR-BI, which relates to its ability to deliver LDL into arteries. On the other hand, SR-BI has also been implicated in transport of HDL to the sub-intimal space as a part of reverse cholesterol transport. SR-BI mediates internalization and transcellular transport of both HDL and LDL, and the cellular and molecular mechanism of the process has just begun to emerge. Harnessing these dual transport functions of the endothelial SR-BI may provide a novel, effective intervention to atherosclerosis.

Indexed as

AtherosclerosisEndothelial CellsAnimalsEndotheliumHumansMiceScavenger Receptors, Class BSignal TransductionScavenger Receptors, Class BAtherosclerosisEndotheliumScavenger receptor type B class ITranscytosis

Identifiers

PMID33420646
PMCPMC8918055
OpenAlexW3119738815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.